Kunal Paul, PhD

Researcher
Optum, India

Poster(s):

• (213) What evidence packages did CMS consider for Maximum Fair Price determination? A comparative analysis of Apixaban, Rivaroxaban and Sacubitril/Valsartan
  Wednesday, October 29, 2025